Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
151. |
ECCT/17/05/02 | The Anza Mapema Study Expanding test and treat for HIV prevention in MSM in Kisumu, Kenya: The Anza Mapema Study |
Principal Investigator(s) 1. Fredrick Odhiambo Otieno Site(s) in Kenya Anza Mapema Study Clinic |
01-09-2017 |
View |
152. |
ECCT/17/05/03 | TDF IVR-002 Study Phase 1 Safety and Pharmacokinetic Study of a Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring in Sexually Active Women (TDF IVR-002) |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya Partners in Health Research & Development (Thika Partners Clinical Trial Site) |
18-07-2017 |
View |
153. |
ECCT/17/05/04 | Ad26.Mos4.HIV Prime/Ad26.Mos4.HIV with Clade C gp140 plus adjuvant +/- Mosaic boost A randomized, parallel-group, placebo-controlled, double-blind Phase 1/2a study in healthy HIV-uninfected adults to assess safety/tolerability and immunogenicity of 2 different prime/boost regimens: priming with tetravalent Ad26.Mos4.HIV and boosting with tetravalent Ad26.Mos4.HIV and either Clade C gp140 plus adjuvant OR a combination of Mosaic and Clade C gp140 plus adjuvant |
Principal Investigator(s) 1. Josphat Kosgei Site(s) in Kenya KEMRI WALTER REED KERICHO |
07-07-2017 |
View |
154. |
ECCT/17/06/01 | MF/PM Phase III An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin with Sodium Stibogluconate and Paromomycin Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa |
Principal Investigator(s) 1. Jane Mbui Site(s) in Kenya 1. Kimalel Health Centre (Baringo county) 2. Kacheliba sub-county hospital (West Pokot county) |
04-10-2017 |
View |
155. |
ECCT/17/06/02 | PAINT Study A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years |
Principal Investigator(s) 1. Isaac Tsikhutsu Site(s) in Kenya 1. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county) 2. KAVI Institute of Clinical Research (Nairobi City county) |
10-10-2017 |
View |
156. |
ECCT/17/07/01 | ABCD Antibiotics for Children with Severe Diarrhea Trial |
Principal Investigator(s) 1. Judd Walson Site(s) in Kenya 1. Rongo Sub-County Hospital (Migori county) 2. Ndhiwa Sub-County Hospital (Homa Bay county) 3. Rachuonyo Sub-County Hospital (Homa Bay county) 4. Isebania Sub-County Hospital (Migori county) 5. Awendo Sub-County Hospital (Migori county) 6. Mbita Sub-County Hospital (Homa Bay county) |
01-12-2017 |
View |
157. |
ECCT/17/08/01 | A trial to compare the safety and immune response of the normal full and reduced doses of yellow fever vaccines in Kenyan adults A Phase IV randomized, double blinded non-inferiority trial on the immunogenicity and safety of fractional doses of yellow fever vaccines. |
Principal Investigator(s) 1. Philip Bejon Site(s) in Kenya KEMRI Kilifi |
07-09-2017 |
View |
158. |
ECCT/17/08/02 | IMPROVE (Improving PRegnancy Outcomes with intermittent PReVEntive treatment in Africa) IPTp with dihydroartemisinin-piperaquine and azithromycin for malaria, sexually transmitted and reproductive tract infections in pregnancy in high sulphadoxine-pyrimethamine resistance areas in Kenya, Malawi and Tanzania: an international multi-centre 3-arm placebo-controlled trial |
Principal Investigator(s) 1. Simon Kariuki Site(s) in Kenya 1. Migori County Referral Hospital (Migori county) 2. Homa Bay County Referral Hospital (Homa Bay county) 3. Rongo Sub-County Hospital (Migori county) 4. Ahero Sub-County Hospital (Kisumu county) 5. Rabuor Sub-County Hospital (Kisumu county) |
07-09-2017 |
View |
159. |
ECCT/17/08/03 | Efficacy and safety of KAF156 in combination with LUM-SDF in adults and children with uncomplicated Plasmodium falciparum malaria A Phase 2 interventional, multicenter, randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersion Formulation in combination, given once daily for 1, 2 and 3-days to adults and children with uncomplicated Plasmodium falciparum malaria. |
Principal Investigator(s) 1. Grace Kiringa Kaguthi Site(s) in Kenya KEMRI Siaya |
02-10-2017 |
View |
160. |
ECCT/17/08/04 | P1081 A PHASE IV RANDOMIZED TRIAL TO EVALUATE THE VIROLOGIC RESPONSE AND PHARMACOKINETICS OF TWO DIFFERENT POTENT REGIMENS IN HIV INFECTED WOMEN INITIATING TRIPLE ANTIRETROVIRAL REGIMENS BETWEEN 28 AND 36 WEEKS OF PREGNANCY FOR THE PREVENTION OF MOTHER-TO-CHILD TRANSMISSION: NICHD P1081 |
Principal Investigator(s) 1. FREDRICK KIPYEGON SAWE Site(s) in Kenya Kenya Medical Research Institute Walter Reed Project Clinical Research Centre. |
13-11-2017 |
View |